Exploring the binding dynamics of covalent inhibitors within active site of PLpro in SARS-CoV-2
Graphical Abstract
Display Omitted
References
[1]
A. Artese, V. Svicher, G. Costa, R. Salpini, V.C. Di Maio, M. Alkhatib, F.A. Ambrosio, M.M. Santoro, Y.G. Assaraf, S. Alcaro, Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses, Drug Resist. Updates 53 (2020).
[2]
I.M. Artika, A.K. Dewantari, A. Wiyatno, Molecular biology of coronaviruses: current knowledge, Heliyon 6 (2020).
[3]
K.M. Backus, B.E. Correia, K.M. Lum, S. Forli, B.D. Horning, G.E. González-Páez, S. Chatterjee, B.R. Lanning, J.R. Teijaro, A.J. Olson, Proteome-wide covalent ligand discovery in native biological systems, Nature 534 (2016) 570–574.
[4]
Y.M. Báez-Santos, S.E.S. John, A.D. Mesecar, The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds, Antivir. Res. 115 (2015) 21–38.
[5]
N. Barretto, D. Jukneliene, K. Ratia, Z. Chen, A.D. Mesecar, S.C. Baker, The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity, J. Virol. 79 (2005) 15189–15198.
[6]
D. Benvenuto, M. Giovanetti, A. Ciccozzi, S. Spoto, S. Angeletti, M. Ciccozzi, The 2019-new coronavirus epidemic: evidence for virus evolution, J. Med. Virol. 92 (2020) 455–459.
[7]
J. Cui, F. Li, Z.-L. Shi, Origin and evolution of pathogenic coronaviruses, Nat. Rev. Microbiol. 17 (2019) 181–192.
[8]
S. De Cesco, J. Kurian, C. Dufresne, A.K. Mittermaier, N. Moitessier, Covalent inhibitors design and discovery, Eur. J. Med. Chem. 138 (2017) 96–114.
[9]
C.P. Delgado, J.B.T. Rocha, L. Orian, M. Bortoli, P.A. Nogara, In silico studies of Mpro and PLpro from SARS-CoV-2 and a new class of cephalosporin drugs containing 1, 2, 4-thiadiazole, Struct. Chem. 33 (2022) 2205–2220.
[10]
S.G. Devaraj, N. Wang, Z. Chen, Z. Chen, M. Tseng, N. Barretto, R. Lin, C.J. Peters, C.-T.K. Tseng, S.C. Baker, Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus, J. Biol. Chem. 282 (2007) 32208–32221.
[11]
A.W. Edridge, J. Kaczorowska, A.C. Hoste, M. Bakker, M. Klein, M.F. Jebbink, A. Matser, C.M. Kinsella, P. Rueda, M. Prins, Human coronavirus reinfection dynamics: lessons for SARS-CoV-2, MedRxiv 2020 (2020) 05. 11.20086439.
[12]
Z. Fu, B. Huang, J. Tang, S. Liu, M. Liu, Y. Ye, Z. Liu, Y. Xiong, W. Zhu, D. Cao, The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery, Nat. Commun. 12 (2021) 488.
[13]
X. Gao, B. Qin, P. Chen, K. Zhu, P. Hou, J.A. Wojdyla, M. Wang, S. Cui, Crystal structure of SARS-CoV-2 papain-like protease, Acta Pharm. Sin. B 11 (2021) 237–245.
[14]
S.K. Gayatri, V. Chhabra, H. Kumar, M.E. Sobhia, Identification of prospective covalent inhibitors for SARS-CoV-2 main protease using structure-based approach, J. Biomol. Struct. Dyn. (2022) 1–18.
[15]
S.K. Gayatri, V. Chhabra, H. Kumar, M.E. Sobhia, Identification of prospective covalent inhibitors for SARS-CoV-2 main protease using structure-based approach, J. Biomol. Struct. Dyn. 41 (2023) 7913–7930.
[16]
Y.-S. Han, G.-G. Chang, C.-G. Juo, H.-J. Lee, S.-H. Yeh, J.T.-A. Hsu, X. Chen, Papain-like protease 2 (PLP2) from severe acute respiratory syndrome coronavirus (SARS-CoV): expression, purification, characterization, and inhibition, Biochemistry 44 (2005) 10349–10359.
[17]
B.H. Harcourt, D. Jukneliene, A. Kanjanahaluethai, J. Bechill, K.M. Severson, C.M. Smith, P.A. Rota, S.C. Baker, Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity, J. Virol. 78 (2004) 13600–13612.
[18]
S.A. Hollingsworth, R.O. Dror, Molecular dynamics simulation for all, Neuron 99 (2018) 1129–1143.
[19]
D. Jade, S. Ayyamperumal, V. Tallapaneni, C.M.J. Nanjan, S. Barge, S. Mohan, M.J. Nanjan, Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PLPRO and 3CLPRO proteases, Eur. J. Pharmacol. 901 (2021).
[20]
G. Kalibaeva, M. Ferrario, G. Ciccotti, Constant pressure-constant temperature molecular dynamics: a correct constrained NPT ensemble using the molecular virial, Mol. Phys. 101 (2003) 765–778.
[21]
S. Khare, C. Gurry, L. Freitas, M.B. Schultz, G. Bach, A. Diallo, N. Akite, J. Ho, R.T. Lee, W. Yeo, GISAID’s role in pandemic response, China CDC Wkly. 3 (2021) 1049.
[22]
H. Kim, D. Hauner, J.A. Laureanti, K. Agustin, S. Raugei, N. Kumar, Mechanistic investigation of SARS-CoV-2 main protease to accelerate design of covalent inhibitors, Sci. Rep. 12 (2022).
[23]
A. Koirala, Y.J. Joo, A. Khatami, C. Chiu, P.N. Britton, Vaccines for COVID-19: the current state of play, Paediatr. Respir. Rev. 35 (2020) 43–49.
[24]
S.S. Krishna, I. Majumdar, N.V. Grishin, Survey and summary: structural classification of zinc fingers, Nucleic Acids Res. 31 (2003) 532.
[25]
H.A. Lindner, N. Fotouhi-Ardakani, V. Lytvyn, P. Lachance, T. Sulea, R. Ménard, The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme, J. Virol. 79 (2005) 15199–15208.
[26]
R. Lonsdale, R.A. Ward, Structure-based design of targeted covalent inhibitors, Chem. Soc. Rev. 47 (2018) 3816–3830.
[27]
C. Ma, M.D. Sacco, Z. Xia, G. Lambrinidis, J.A. Townsend, Y. Hu, X. Meng, T. Szeto, M. Ba, X. Zhang, Discovery of SARS-CoV-2 papain-like protease inhibitors through a combination of high-throughput screening and a FlipGFP-based reporter assay, ACS Cent. Sci. 7 (2021) 1245–1260.
[28]
F. Madeira, M. Pearce, A.R. Tivey, P. Basutkar, J. Lee, O. Edbali, N. Madhusoodanan, A. Kolesnikov, R. Lopez, Search and sequence analysis tools services from EMBL-EBI in 2022, Nucleic Acids Res. 50 (2022) W276–W279.
[29]
R. Mah, J.R. Thomas, C.M. Shafer, Drug discovery considerations in the development of covalent inhibitors, Bioorg. Med. Chem. Lett. 24 (2014) 33–39.
[30]
Y.A. Malik, Properties of coronavirus and SARS-CoV-2, Malays. J. Pathol. 42 (2020) 3–11.
[31]
J. Osipiuk, S.-A. Azizi, S. Dvorkin, M. Endres, R. Jedrzejczak, K.A. Jones, S. Kang, R.S. Kathayat, Y. Kim, V.G. Lisnyak, Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors, Nat. Commun. 12 (2021) 743.
[32]
A.K. Padhi, S.L. Rath, T. Tripathi, Accelerating COVID-19 research using molecular dynamics simulation, J. Phys. Chem. B 125 (2021) 9078–9091.
[33]
A. Palayew, O. Norgaard, K. Safreed-Harmon, T.H. Andersen, L.N. Rasmussen, J.V. Lazarus, Pandemic publishing poses a new COVID-19 challenge, Nat. Hum. Behav. 4 (2020) 666–669.
[34]
S. Rauch, E. Jasny, K.E. Schmidt, B. Petsch, New vaccine technologies to combat outbreak situations, Front. Immunol. 9 (2018) 1963.
[35]
G.S. Rieder, P.A. Nogara, F.B. Omage, T. Duarte, C.L. Dalla Corte, J.B.T. da Rocha, Computational analysis of the interactions between Ebselen and derivatives with the active site of the main protease from SARS-CoV-2, Comput. Biol. Chem. 107 (2023).
[36]
R.L. Roper, K.E. Rehm, SARS vaccines: where are we?, Expert Rev. Vaccin. 8 (2009) 887–898.
[37]
W. Rut, Z. Lv, M. Zmudzinski, S. Patchett, D. Nayak, S.J. Snipas, F. El Oualid, T.T. Huang, M. Bekes, M. Drag, Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: a framework for anti–COVID-19 drug design, Sci. Adv. 6 (2020) eabd4596.
[38]
B. Sanders, S. Pohkrel, A. Labbe, I. Mathews, C. Cooper, R. Davidson, G. Phillips, K. Weiss, Q. Zhang, H. O’Neill, Research square, Potent Sel. covalent Inhib. papain- Protease SARS-CoV-2 (2021).
[39]
B.C. Sanders, S. Pokhrel, A.D. Labbe, I.I. Mathews, C.J. Cooper, R.B. Davidson, G. Phillips, K.L. Weiss, Q. Zhang, H. O’Neill, Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2, Nat. Commun. 14 (2023) 1733.
[40]
S. Satarker, M. Nampoothiri, Structural proteins in severe acute respiratory syndrome coronavirus-2, Arch. Med. Res. 51 (2020) 482–491.
[41]
D. Schoeman, B.C. Fielding, Coronavirus envelope protein: current knowledge, Virol. J. 16 (2019) 1–22.
[42]
Z. Shen, K. Ratia, L. Cooper, D. Kong, H. Lee, Y. Kwon, Y. Li, S. Alqarni, F. Huang, O. Dubrovskyi, Design of SARS-CoV-2 PLpro inhibitors for COVID-19 antiviral therapy leveraging binding cooperativity, J. Med. Chem. 65 (2021) 2940–2955.
[43]
Z. Shen, K. Ratia, L. Cooper, D. Kong, H. Lee, Y. Kwon, Y. Li, S. Alqarni, F. Huang, O. Dubrovskyi, Potent, novel SARS-CoV-2 PLpro inhibitors block viral replication in monkey and human cell cultures, BioRxiv (2021) 2021.02. 13.431008.
[44]
D. Shin, R. Mukherjee, D. Grewe, D. Bojkova, K. Baek, A. Bhattacharya, L. Schulz, M. Widera, A.R. Mehdipour, G. Tascher, Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity, Nature 587 (2020) 657–662.
[45]
J. Singh, The ascension of targeted covalent inhibitors, J. Med. Chem. 65 (2022) 5886–5901.
[46]
F. Sutanto, M. Konstantinidou, A. Dömling, Covalent inhibitors: a rational approach to drug discovery, RSC Med. Chem. 11 (2020) 876–884.
[47]
H. Tan, Y. Hu, P. Jadhav, B. Tan, J. Wang, Progress and challenges in targeting the SARS-CoV-2 papain-like protease, J. Med. Chem. 65 (2022) 7561–7580.
[48]
B. Tan, X. Zhang, A. Ansari, P. Jadhav, H. Tan, K. Li, A. Chopra, A. Ford, X. Chi, F.X. Ruiz, Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model, Science 383 (2024) 1434–1440.
[49]
Y.-F. Tu, C.-S. Chien, A.A. Yarmishyn, Y.-Y. Lin, Y.-H. Luo, Y.-T. Lin, W.-Y. Lai, D.-M. Yang, S.-J. Chou, Y.-P. Yang, A review of SARS-CoV-2 and the ongoing clinical trials, Int. J. Mol. Sci. 21 (2020) 2657.
[50]
E. Weglarz-Tomczak, J.M. Tomczak, M. Talma, M. Burda-Grabowska, M. Giurg, S. Brul, Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2, Sci. Rep. 11 (2021) 1–10.
[51]
C. Wu, Y. Liu, Y. Yang, P. Zhang, W. Zhong, Y. Wang, Q. Wang, Y. Xu, M. Li, X. Li, Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods, Acta Pharm. Sin. B 10 (2020) 766–788.
[52]
A.A. Yameny, The COVID-19 JN. 1 variant diagnosed in Egypt, J. Med. Life Sci. 5 (2023) 318–321.
Index Terms
- Exploring the binding dynamics of covalent inhibitors within active site of PLpro in SARS-CoV-2
Index terms have been assigned to the content through auto-classification.
Recommendations
Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery
AbstractWith numerous infections and fatalities, COVID-19 has wreaked havoc around the globe. The main protease (Mpro), which cleaves the polyprotein to form non-structural proteins, thereby helping in the replication of SARS-CoV-2, appears as an ...
Graphical abstractDisplay Omitted
Highlights- All protease inhibitor, antiviral, and antimalarial FDA-approved drugs were screened against the SARS-CoV-2 main protease.
- 53 drugs exhibited interaction energy with Mpro below −7.0 kcal/mol and their pKi values were predicted.
- ...
Identification of Potential SARS-CoV-2 Main Protease Inhibitors Using Drug Repurposing and Molecular Modeling
Bioinformatics Research and ApplicationsAbstractStructure-based virtual screening of a molecular library of bioactive compounds was carried out to identify potential inhibitors against SARS-CoV-2 main protease (Mpro), an enzyme critically important for mediating viral replication and ...
SARS-CoV-2 proteases Mpro and PLpro: Design of inhibitors with predicted high potency and low mammalian toxicity using artificial neural networks, ligand-protein docking, molecular dynamics simulations, and ADMET calculations
AbstractThe main (Mpro) and papain-like (PLpro) proteases are highly conserved viral proteins essential for replication of the COVID-19 virus, SARS-COV-2. Therefore, a logical plan for producing new drugs against this pathogen is to discover inhibitors ...
Graphical abstractDisplay Omitted
Highlights- Pyrazolopyridazines found in silico as new class of potential Mpro/PLpro inhibitors.
- Docking and MD indicate stable binding of lead compounds to catalytic active sites.
- Docking and MD show stable binding of 3 compounds to Mpro ...
Comments
Please enable JavaScript to view thecomments powered by Disqus.Information & Contributors
Information
Published In
Copyright © 2024.
Publisher
Elsevier Science Publishers B. V.
Netherlands
Publication History
Published: 01 October 2024
Author Tags
Qualifiers
- Research-article
Contributors
Other Metrics
Bibliometrics & Citations
Bibliometrics
Article Metrics
- 0Total Citations
- 0Total Downloads
- Downloads (Last 12 months)0
- Downloads (Last 6 weeks)0
Reflects downloads up to 05 Mar 2025